The occurrence of severe seizure is almost always present in hypothalamic hamartomas (HH) cases and surgery is an option to control the condition. Stereotactic radiosurgery (SRS) is among of alternative treatments. Our objective is to provide current evidence for seizure treatment with SRS in HHs patients. From EuroPMC, PubMed, ScienceDirect and the Cochrane Library, each author carried out literature searches on seizure treatment for HH using SRS between 1971 and 2021 using the following terms: stereotactic radiosurgery, radiosurgery, CyberKnife, Gamma Knife, linear accelerator, radiotherapy and hypothalamic hamartoma. We included any patients with seizure onset less than 18 years of age, regardless of age when SRS was performed. This systematic review included 17 out of 31 studies, three of which were observational studies. The study included 131 individuals, with a median age of onset of 7.4 years old and a male-to-female ratio of 34.3% (n=45). The isodose at the margin was 19 Gy. The median lesion volume at the time of diagnosis was 0.8 mL (0.1 – 48.3 mL). The median follow-up after SRS was 34.3 months (3 – 77 months). Only eight of the 90 HHs had a change in MR and 12 patients, SRS had no effect on the seizure frequency. The authors concluded that SRS is beneficial for the treatment of HH. However, the authors could not deny that current evidence is too early to construct a systematic review and a more prospective study design is required.
{"title":"Stereotactic Radiosurgery in the Management of Intractable Seizure Due to Hypothalamic Hamartoma","authors":"J. H. Wijaya","doi":"10.46889/jnor.2024.4206","DOIUrl":"https://doi.org/10.46889/jnor.2024.4206","url":null,"abstract":"The occurrence of severe seizure is almost always present in hypothalamic hamartomas (HH) cases and surgery is an option to control the condition. Stereotactic radiosurgery (SRS) is among of alternative treatments. Our objective is to provide current evidence for seizure treatment with SRS in HHs patients. From EuroPMC, PubMed, ScienceDirect and the Cochrane Library, each author carried out literature searches on seizure treatment for HH using SRS between 1971 and 2021 using the following terms: stereotactic radiosurgery, radiosurgery, CyberKnife, Gamma Knife, linear accelerator, radiotherapy and hypothalamic hamartoma. We included any patients with seizure onset less than 18 years of age, regardless of age when SRS was performed. This systematic review included 17 out of 31 studies, three of which were observational studies. The study included 131 individuals, with a median age of onset of 7.4 years old and a male-to-female ratio of 34.3% (n=45). The isodose at the margin was 19 Gy. The median lesion volume at the time of diagnosis was 0.8 mL (0.1 – 48.3 mL). The median follow-up after SRS was 34.3 months (3 – 77 months). Only eight of the 90 HHs had a change in MR and 12 patients, SRS had no effect on the seizure frequency. The authors concluded that SRS is beneficial for the treatment of HH. However, the authors could not deny that current evidence is too early to construct a systematic review and a more prospective study design is required.","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"23 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141814404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Vestibular Schwannoma (VS) and breast cancer patients experience negative Quality of Life (QoL) impacts. VS patients struggle with mood disorders, whereas breast cancer patients experience treatment-related cognitive impairment. Improving QoL in these patient populations is the objective of these digital app technologies involving music, art and robotic pet therapies. Methods: Active Receptive Music for Cancer (ARMCan) recruited ten breast cancer patients who were randomized into an interactive music therapy group and a receptive music therapy group, occurring daily for 15 minutes over 6 months. The primary endpoint was Functional Assessment of Cancer Therapy – Cognitive Function (FACT-Cog) scores. Sensory Integrative Therapy with Art and Robots (SITAR) recruited ten VS patients to undergo art therapy alone or art therapy and robotic companion therapy weekly for twelve weeks. One patient in each group completed the study. The primary endpoint was Mental Health Quality of Life Questionnaire (MHQOL) surveys with a secondary endpoint of Hamilton Depression scale (HAM-D). Results: For ARMCan, integrative music therapy led to an increase in FACT-Cog scores of 44.2% and 12.4% for the interactive (n = 3) and receptive music (n = 3) groups, respectively. For SITAR, there were 106% and 63.6% increases in MHQOL scores for the art intervention (n = 1) and combined therapy groups (n = 1), respectively. There was an average decrease of 80% in HAM-D scores. Conclusion: This pilot study primarily demonstrates feasibility for digital applications to improve QoL in breast cancer and VS patients. There is preliminary data to support that integrative music therapy can improve treatment-induced cognitive impairment in breast cancer patients. Similarly, art and robotic animal companion therapy may improve overall QoL and reduce depressive symptoms in vestibular schwannoma patients.
目的：前庭神经管瘤（VS）和乳腺癌患者的生活质量（QoL）会受到负面影响。前庭神经丛神经瘤患者会出现情绪障碍，而乳腺癌患者则会出现与治疗相关的认知障碍。改善这些患者群体的生活质量是这些涉及音乐、艺术和机器人宠物疗法的数字应用技术的目标：方法：Active Receptive Music for Cancer（ARMCan）招募了 10 名乳腺癌患者，将他们随机分为交互式音乐治疗组和接受式音乐治疗组，每天治疗 15 分钟，为期 6 个月。主要终点是癌症治疗功能评估--认知功能（FACT-Cog）评分。艺术与机器人感官综合疗法（SITAR）招募了 10 名 VS 患者，让他们接受单独的艺术疗法或艺术疗法与机器人辅助疗法，每周一次，为期 12 周。每组各有一名患者完成研究。研究的主要终点是心理健康生活质量问卷调查（MHQOL），次要终点是汉密尔顿抑郁量表（HAM-D）：对于 ARMCan，综合音乐疗法使互动组（3 人）和接受音乐组（3 人）的 FACT-Cog 分数分别提高了 44.2% 和 12.4%。对于 SITAR，艺术干预组（n = 1）和综合治疗组（n = 1）的 MHQOL 分数分别提高了 106% 和 63.6%。HAM-D 评分平均下降了 80%：这项试点研究主要证明了数字应用改善乳腺癌和 VS 患者 QoL 的可行性。有初步数据支持综合音乐疗法可以改善乳腺癌患者因治疗引起的认知障碍。同样，艺术和机器人动物伴侣疗法可改善前庭裂隙瘤患者的整体生活质量，减轻抑郁症状。
{"title":"Pilot Testing of CAN Digital Apps to Improve the Quality of Life of Cancer and Benign Brain Tumor Survivors","authors":"Claudia Rebola","doi":"10.46889/jnor.2024.4204","DOIUrl":"https://doi.org/10.46889/jnor.2024.4204","url":null,"abstract":"Objective: Vestibular Schwannoma (VS) and breast cancer patients experience negative Quality of Life (QoL) impacts. VS patients struggle with mood disorders, whereas breast cancer patients experience treatment-related cognitive impairment. Improving QoL in these patient populations is the objective of these digital app technologies involving music, art and robotic pet therapies.\u0000\u0000Methods: Active Receptive Music for Cancer (ARMCan) recruited ten breast cancer patients who were randomized into an interactive music therapy group and a receptive music therapy group, occurring daily for 15 minutes over 6 months. The primary endpoint was Functional Assessment of Cancer Therapy – Cognitive Function (FACT-Cog) scores. Sensory Integrative Therapy with Art and Robots (SITAR) recruited ten VS patients to undergo art therapy alone or art therapy and robotic companion therapy weekly for twelve weeks. One patient in each group completed the study. The primary endpoint was Mental Health Quality of Life Questionnaire (MHQOL) surveys with a secondary endpoint of Hamilton Depression scale (HAM-D).\u0000\u0000Results: For ARMCan, integrative music therapy led to an increase in FACT-Cog scores of 44.2% and 12.4% for the interactive (n = 3) and receptive music (n = 3) groups, respectively. For SITAR, there were 106% and 63.6% increases in MHQOL scores for the art intervention (n = 1) and combined therapy groups (n = 1), respectively. There was an average decrease of 80% in HAM-D scores.\u0000\u0000Conclusion: This pilot study primarily demonstrates feasibility for digital applications to improve QoL in breast cancer and VS patients. There is preliminary data to support that integrative music therapy can improve treatment-induced cognitive impairment in breast cancer patients. Similarly, art and robotic animal companion therapy may improve overall QoL and reduce depressive symptoms in vestibular schwannoma patients.","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"35 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141355568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pleural effusion, the pathological accumulation of fluid in the pleural space, is very common. Its causes vary widely, ranging from fairly harmless effusions accompanying viral pleuritis to prognostically highly relevant ones due to congestive heart failure or malignances. Pleural effusions are classified by their biochemical properties into exudative and transudative effusions but can also be due to blood, pus and chyle. Applying Light’s criteria may be helpful to diagnose an exudative effusion. Exudative effusions are commonly caused by infection, malignancy and inflammatory disorders, such as rheumatoid arthritis. In this case we presented 39 women that was admentes with only short of breath and Pleural effusion, During the hospitalization, a pleural fluid puncture was performed and a cytological result was obtained for ovarian cancer and CA-125 was high in the pleural fluid, the patient underwent chemotherapy and her condition improved hourly. In this case, we present a rare case in which the patient complained of shortness of breath without surgical or gynecological complaints and was finally diagnosed with ovarian cancer, which raises the importance of ruling out malignancy every time a new pleural fluid is aspirated.
{"title":"Plueral Effusion and Ovarian Cancer","authors":"Mohammad Haydar","doi":"10.46889/jnor.2024.4106","DOIUrl":"https://doi.org/10.46889/jnor.2024.4106","url":null,"abstract":"Pleural effusion, the pathological accumulation of fluid in the pleural space, is very common. Its causes vary widely, ranging from fairly harmless effusions accompanying viral pleuritis to prognostically highly relevant ones due to congestive heart failure or malignances. Pleural effusions are classified by their biochemical properties into exudative and transudative effusions but can also be due to blood, pus and chyle. Applying Light’s criteria may be helpful to diagnose an exudative effusion.\u0000\u0000Exudative effusions are commonly caused by infection, malignancy and inflammatory disorders, such as rheumatoid arthritis.\u0000\u0000In this case we presented 39 women that was admentes with only short of breath and Pleural effusion, During the hospitalization, a pleural fluid puncture was performed and a cytological result was obtained for ovarian cancer and CA-125 was high in the pleural fluid, the patient underwent chemotherapy and her condition improved hourly.\u0000\u0000In this case, we present a rare case in which the patient complained of shortness of breath without surgical or gynecological complaints and was finally diagnosed with ovarian cancer, which raises the importance of ruling out malignancy every time a new pleural fluid is aspirated.","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"37 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140671647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
High-grade gliomas represent the most prevalent primary malignant brain tumors in the adult population. Despite extensive efforts dedicated to advance in therapeutic modalities, treatment options remain very limited in this field, leading to a worse prognosis for affected patients. Moreover, a considerable number of cases exhibit refractory disease following the initial management. Ketogenic Metabolic Therapy (KMT) has emerged as a promising adjunctive approach for recurrent high-grade gliomas, offering them a synergistic effect enhancement of the effectiveness of conventional therapies against this type of cancer. The underlying hypothesis relies on the use of high-fat, low-carbohydrate diet, with adequate protein content can potentially induce metabolic reprogramming in cancer cells. Currently, the use of KMT is on the rise and has shown positive effects on the control of selected neurological symptoms and improvements in patient’s quality of life. This is a descriptive observational multicenter study (case series) that includes patients with recurrent high-grade gliomas who underwent Ketogenic Metabolic Therapy (KMT) and were supplemented with a liquid ketogenic formula (in a 3:1 ratio) as a complementary treatment to the ongoing medical regimen for recurrence. The results show a positive impact on seizure control, as well as significant improvements in cognition, memory and functionality, as reported by patients and/or their families (caregivers). Regarding the disease status, assessed by the RANO criteria, the 12-month follow-up evaluation indicated stable disease in 55% and a partial response in 20% of cases. Although the results of this work are promising, more conclusive clinical data are still needed to support the use of KMT in the treatment of high-grade gliomas.
{"title":"The Effect of Ketogenic Metabolic Therapy on Recurrent High-Grade Gliomas: Case Series","authors":"","doi":"10.46889/jnor.2024.4103","DOIUrl":"https://doi.org/10.46889/jnor.2024.4103","url":null,"abstract":"High-grade gliomas represent the most prevalent primary malignant brain tumors in the adult population. Despite extensive efforts dedicated to advance in therapeutic modalities, treatment options remain very limited in this field, leading to a worse prognosis for affected patients. Moreover, a considerable number of cases exhibit refractory disease following the initial management. Ketogenic Metabolic Therapy (KMT) has emerged as a promising adjunctive approach for recurrent high-grade gliomas, offering them a synergistic effect enhancement of the effectiveness of conventional therapies against this type of cancer. The underlying hypothesis relies on the use of high-fat, low-carbohydrate diet, with adequate protein content can potentially induce metabolic reprogramming in cancer cells. Currently, the use of KMT is on the rise and has shown positive effects on the control of selected neurological symptoms and improvements in patient’s quality of life. This is a descriptive observational multicenter study (case series) that includes patients with recurrent high-grade gliomas who underwent Ketogenic Metabolic Therapy (KMT) and were supplemented with a liquid ketogenic formula (in a 3:1 ratio) as a complementary treatment to the ongoing medical regimen for recurrence. The results show a positive impact on seizure control, as well as significant improvements in cognition, memory and functionality, as reported by patients and/or their families (caregivers). Regarding the disease status, assessed by the RANO criteria, the 12-month follow-up evaluation indicated stable disease in 55% and a partial response in 20% of cases. Although the results of this work are promising, more conclusive clinical data are still needed to support the use of KMT in the treatment of high-grade gliomas.","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"202 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140704699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Ventriculoperitoneal shunt (VP) insertion is one of the surgical treatments for patients with hydrocephalus. Infection, malfunction, catheter migration, hernia development, equipment failure, CSF subcutaneous collection and peritoneal pseudocyst formation are considered to be the main complications of this procedure. Case Description: A 6-months-old boy known to have congenital aqueductal stenosis with VP shunt insertion at the age of 1 month, presented with scrotal swelling and generalized hypotonia. He was found to have catheter migration into the scrotum. Conclusion: Scrotal migration of the distal end of the ventriculoperitoneal shunt is a rare but threatening complication that can present with either signs of hydrocephalus or scrotal swelling or hydrocele. Accordingly, we recommend performing a scrotal exam with an ultrasound early upon evaluation of any infant presenting with scrotal swelling or hydrocele after VP shunt insertion. There haven’t been clear recommendations in the literature concerning closure of patent processus vaginalis upon placing a VP shunt in patients below the age of 3 months. Thus, we question whether early closure could help reduce the complications of catheter migration in infants.
{"title":"Scrotal Migration of The Distal End of The Ventriculoperitoneal Shunt: Is There a Role for Early Closure of Patent Processus Vaginalis in The Pediatric Population?","authors":"Houssein Darwish","doi":"10.46889/jnor.2024.4102","DOIUrl":"https://doi.org/10.46889/jnor.2024.4102","url":null,"abstract":"Background: Ventriculoperitoneal shunt (VP) insertion is one of the surgical treatments for patients with hydrocephalus. Infection, malfunction, catheter migration, hernia development, equipment failure, CSF subcutaneous collection and peritoneal pseudocyst formation are considered to be the main complications of this procedure.\u0000\u0000Case Description: A 6-months-old boy known to have congenital aqueductal stenosis with VP shunt insertion at the age of 1 month, presented with scrotal swelling and generalized hypotonia. He was found to have catheter migration into the scrotum.\u0000\u0000Conclusion: Scrotal migration of the distal end of the ventriculoperitoneal shunt is a rare but threatening complication that can present with either signs of hydrocephalus or scrotal swelling or hydrocele. Accordingly, we recommend performing a scrotal exam with an ultrasound early upon evaluation of any infant presenting with scrotal swelling or hydrocele after VP shunt insertion. There haven’t been clear recommendations in the literature concerning closure of patent processus vaginalis upon placing a VP shunt in patients below the age of 3 months. Thus, we question whether early closure could help reduce the complications of catheter migration in infants.","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"26 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140435690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Glioblastoma is the most common primary, malignant adult brain tumor with a median overall survival of 12-15 months after diagnosis. The standard of care includes maximal safe resection, chemoradiation, adjuvant chemotherapy with the DNA alkylator, temozolomide and tumor-treating fields. Given the recent advances in targeted molecular therapeutics and tissue sequencing, there is a growing opportunity for precision medicine in GBM treatment. In this case report, we present two patients who were found to have EGFR amplifications on molecular analysis and were treated with the EGFR inhibitor, osimertinib (Tagrisso), in combination with bevacizumab (Avastin) after tumor progression. One patient received osimertinib at first GBM progression, while the other patient received osimertinib after two other treatment regimens had failed. Both patients displayed radiographic stability several months after the expected median overall survival rate of 15 months post-diagnosis for GBM. This case report offers clinical vignettes in support of the use of EGFR inhibitors and bevacizumab in recurrent GBM with EGFR mutations.
{"title":"Osimertinib in Combination with Bevacizumab for EGFR Mutated Recurrent Glioblastoma (GBM): A Case Report","authors":"Soma Sengupta","doi":"10.46889/jnor.2024.4101","DOIUrl":"https://doi.org/10.46889/jnor.2024.4101","url":null,"abstract":"Glioblastoma is the most common primary, malignant adult brain tumor with a median overall survival of 12-15 months after diagnosis. The standard of care includes maximal safe resection, chemoradiation, adjuvant chemotherapy with the DNA alkylator, temozolomide and tumor-treating fields. Given the recent advances in targeted molecular therapeutics and tissue sequencing, there is a growing opportunity for precision medicine in GBM treatment. In this case report, we present two patients who were found to have EGFR amplifications on molecular analysis and were treated with the EGFR inhibitor, osimertinib (Tagrisso), in combination with bevacizumab (Avastin) after tumor progression. One patient received osimertinib at first GBM progression, while the other patient received osimertinib after two other treatment regimens had failed. Both patients displayed radiographic stability several months after the expected median overall survival rate of 15 months post-diagnosis for GBM. This case report offers clinical vignettes in support of the use of EGFR inhibitors and bevacizumab in recurrent GBM with EGFR mutations.","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"43 44","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139528037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A posterior fossa dural arteriovenous fistula presenting clinically as a carotid-cavernous fistula is a very rare and relatively unknown situation. They present with several clinical symptoms due to abnormal or excessive blood flowing into the cavernous sinuses. Although abnormal shunts between two vascular domains near each other may be expected (as in carotid-cavernous fistulas), an abnormal shunt from a distant artery to a cavernous venous sinus would be something unusual. Endovascular treatment is now the first-line, safest and cost-effective treatment for this type of fistula. In this paper, we report a very rare situation (a spontaneous posterior fossa dural arteriovenous fistula presenting clinically as a carotid-cavernous fistula) that is treated with endovenous intervention and coil embolization. The importance of other cavernous sinus-related fistulas, their diagnostic features and therapeutic options will also be discussed in this paper.
{"title":"Diagnosis and Minimally-Invasive Treatment of Posterior Fossa Dural Arteriovenous Fistula Presenting Clinically as A Carotid-Cavernous Fistula","authors":"O. Algın","doi":"10.46889/jnor.2023.3304","DOIUrl":"https://doi.org/10.46889/jnor.2023.3304","url":null,"abstract":"A posterior fossa dural arteriovenous fistula presenting clinically as a carotid-cavernous fistula is a very rare and relatively unknown situation. They present with several clinical symptoms due to abnormal or excessive blood flowing into the cavernous sinuses. Although abnormal shunts between two vascular domains near each other may be expected (as in carotid-cavernous fistulas), an abnormal shunt from a distant artery to a cavernous venous sinus would be something unusual. Endovascular treatment is now the first-line, safest and cost-effective treatment for this type of fistula. In this paper, we report a very rare situation (a spontaneous posterior fossa dural arteriovenous fistula presenting clinically as a carotid-cavernous fistula) that is treated with endovenous intervention and coil embolization. The importance of other cavernous sinus-related fistulas, their diagnostic features and therapeutic options will also be discussed in this paper.","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"111 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139133346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast Cancer (BC) is a global health issue and it impacts women around the world. Breast Cancer accounts for 11.7% of all newly diagnosed cancer cases and has become the leading cause of cancer worldwide. In the earliest stages, the survival rate is nearly 100 percent. However, for tumors detected in later stages, that rate drops to around 25 percent. Breast Cancer Research Foundation indicated that due to the progress in advocacy, awareness, early intervention, prompt diagnosis and treatment, there has been an overall 40 percent decline in breast cancer deaths over the last 30 years.
{"title":"Breast Cancer Awareness","authors":"","doi":"10.46889/jnor.2023.3303","DOIUrl":"https://doi.org/10.46889/jnor.2023.3303","url":null,"abstract":"Breast Cancer (BC) is a global health issue and it impacts women around the world. Breast Cancer accounts for 11.7% of all newly diagnosed cancer cases and has become the leading cause of cancer worldwide. In the earliest stages, the survival rate is nearly 100 percent. However, for tumors detected in later stages, that rate drops to around 25 percent. Breast Cancer Research Foundation indicated that due to the progress in advocacy, awareness, early intervention, prompt diagnosis and treatment, there has been an overall 40 percent decline in breast cancer deaths over the last 30 years.","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"33 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139175883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The interest of the Health Sciences and Psychology in the relationships between illness and a person’s behavior is certainly not late. Questions and concerns about the interaction between a biological disorder and the way one lives, feels, thinks, etc. the person who suffers, have occupied both medicine and clinical-psychological research and practice for many years. But mainly within the framework of a very new interdisciplinary direction (behavioral medicine – Verhal-tensmedizin), a more thorough investigation of the importance of behavior for the genesis and formation of many diseases and disorders – mental and/or physical – began [1,2]. Forerunners of this direction, with which Behavioral Medicine often collaborates even now, are Psychosomatic Medicine and Medical Psychology. These branches of course emphasize the importance of behavioral factors around health and disease issues, but they give different weight to their investigations, they mainly have a different theoretical background and do not deal so thoroughly with the experimental investigation of the importance of behavior for etiology, form, course and treatment of various diseases [1,2].
{"title":"Behavioral Medicine: A New Perspective in the Field of Health","authors":"P. Theofilou","doi":"10.46889/jnor.2023.3204","DOIUrl":"https://doi.org/10.46889/jnor.2023.3204","url":null,"abstract":"The interest of the Health Sciences and Psychology in the relationships between illness and a person’s behavior is certainly not late. Questions and concerns about the interaction between a biological disorder and the way one lives, feels, thinks, etc. the person who suffers, have occupied both medicine and clinical-psychological research and practice for many years. But mainly within the framework of a very new interdisciplinary direction (behavioral medicine – Verhal-tensmedizin), a more thorough investigation of the importance of behavior for the genesis and formation of many diseases and disorders – mental and/or physical – began [1,2]. Forerunners of this direction, with which Behavioral Medicine often collaborates even now, are Psychosomatic Medicine and Medical Psychology. These branches of course emphasize the importance of behavioral factors around health and disease issues, but they give different weight to their investigations, they mainly have a different theoretical background and do not deal so thoroughly with the experimental investigation of the importance of behavior for etiology, form, course and treatment of various diseases [1,2].","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79964958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cannabis species’ historical use for relieving medical symptoms, through various preparations like smoking, edibles, ointments, balms and others, dates back over 3,000 years ago, initially in the Far East (especially India and China). Subsequent trading routes brought the herb to the Western World, where its consumption reached significant levels, leading to prohibitions in certain situations, such as in 1764 when Emperor Napoleon of France, having encountered the plant during his Egyptian campaign, observed a decrease in combative behaviour among soldiers, prompting restrictions.
{"title":"Cannabis-Based Products and Medical Propaganda: It Cuts Both Ways","authors":"P. Mei","doi":"10.46889/jnor.2023.3203","DOIUrl":"https://doi.org/10.46889/jnor.2023.3203","url":null,"abstract":"Cannabis species’ historical use for relieving medical symptoms, through various preparations like smoking, edibles, ointments, balms and others, dates back over 3,000 years ago, initially in the Far East (especially India and China). Subsequent trading routes brought the herb to the Western World, where its consumption reached significant levels, leading to prohibitions in certain situations, such as in 1764 when Emperor Napoleon of France, having encountered the plant during his Egyptian campaign, observed a decrease in combative behaviour among soldiers, prompting restrictions.","PeriodicalId":73853,"journal":{"name":"Journal of neuro and oncology research","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89174256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：